2,8-二(三氟甲基)-4-甲基喹啉 | 57124-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2,8-二(三氟甲基)-4-甲基喹啉
• 英文名称: 2,8-bis(trifluoromethyl)-4-methylquinoline
• 英文别名: 2,8-Bis-(trifluormethyl)-lepidin；4-methyl-2,8-bis(trifluoromethyl)quinoline
• CAS: 57124-23-9
• 化学式: C₁₂H₇F₆N
• 分子量: 279.185
• InChiKey: HWXMQNMPJULKCQ-UHFFFAOYSA-N

物化性质

• 沸点：
  259.9±35.0 °C(Predicted)
• 密度：
  1.395±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,8-bis(trifluoromethyl)quinolin-4-yl trifluoromethanesulfonate 、 4-trimethylstannylcoumarin 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三苯胂 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以58%的产率得到4-<2,8-bis(trifluoromethyl)-4-quinolinyl>coumarin
  参考文献：
  名称：

  4-香豆素作为新黄酮新方法中有用的试剂

  摘要：

  摘要 4-三甲基甲锡基香豆素 2 可方便地从相应的 4-三氟甲氧基香豆素 1 中获得，与各种芳基碘化物进行 Pd(0)/CuI 共催化的交叉偶联反应，以中等至良好的产率得到 4-芳基香豆素 4。芳基三氟甲磺酸酯作为偶联伙伴的效果较差。

  DOI：

  10.1080/00397919508011837

文献信息

• SUBSTITUTED THIOXANTHENONE AUTOPHAGY INHIBITORS
  申请人：THE CLEVELAND CLINIC FOUNDATION

  公开号：US20170210746A1

  公开（公告）日：2017-07-27

  Autophagy inhibitors useful for the treatment of cancer and other diseases are described. The autophagy inhibitors are a compound of formula: I wherein R 1 is a group selected from lower alkyl, lower alkyl amide, lower alkyl ester, lower alkyl ketone, and lower alkyl ether; R 2 and R 3 are H or a group selected from cycloalkyl, lower alkyl, lower alkyl amide, lower alkyl ester, lower alkyl ketone, and lower alkyl ether; R 4 is a heteroaryl group; and L is a —(CH 2 ) n —X—(CH 2 ) n — group, wherein n is 1, 2, 3, or 4, X is absent, O, S, or N—R 5 , wherein R 5 is H or a lower alkyl group, or a pharmaceutically acceptable salt thereof.

  本文描述了用于治疗癌症和其他疾病的自噬抑制剂。自噬抑制剂是一种化合物，其化学式为：I，其中R1是从低级烷基、低级烷基酰胺、低级烷基酯、低级烷基酮和低级烷基醚中选择的基团；R2和R3为H或从环烷基、低级烷基、低级烷基酰胺、低级烷基酯、低级烷基酮和低级烷基醚中选择的基团；R4是杂环芳基基团；L是—(CH2)n—X—(CH2)n—基团，其中n为1、2、3或4，X为不存在、O、S或N—R5，其中R5为H或低级烷基基团，或其药学上可接受的盐。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Perni Robert B.

  公开号：US20130116169A1

  公开（公告）日：2013-05-09

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是抑制丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且也可用作抗病毒药物。本发明还涉及包含这些化合物的组合物，用于体外使用或用于治疗患有HCV感染的患者。本发明还涉及通过给患者施用包含本发明化合物的组合物来治疗HCV感染的方法。本发明还涉及制备这些化合物的过程。
• NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20140113890A1

  公开（公告）日：2014-04-24

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：ACHILLION PHARMACEUTICALS, INC.

  公开号：US20140328796A1

  公开（公告）日：2014-11-06

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
• US8445430B2
  申请人：——

  公开号：US8445430B2

  公开（公告）日：2013-05-21